Literature DB >> 29680987

SLIT's Prevention of the Allergic March.

Federica Porcaro1, Giovanni Corsello2, Giovanni Battista Pajno3.   

Abstract

PURPOSE OF REVIEW: The progression of atopic disorders from atopic dermatitis in infants to allergic rhinitis and asthma in children, adolescents, and adults defines the allergy march. Allergen immunotherapy is the only causal treatment altering the immunological mechanism underlying the allergic diseases. The sublingual administration route is more acceptable than the subcutaneous one in pediatric age. RECENT
FINDINGS: Several studies show the efficacy and safety profile of sublingual immunotherapy (SLIT) for the treatment of respiratory allergy diseases, but few data are available on its effect of primary and secondary prevention of allergic disease. The purpose of this manuscript is to review the latest studies addressing the effect of SLIT on the development of new sensitizations in not sensitized or already sensitized patients and progression of the allergy march.

Entities:  

Keywords:  Allergen immunotherapy; Allergic march; Primary prevention; Secondary prevention; Sublingual immunotherapy

Mesh:

Year:  2018        PMID: 29680987     DOI: 10.1007/s11882-018-0785-7

Source DB:  PubMed          Journal:  Curr Allergy Asthma Rep        ISSN: 1529-7322            Impact factor:   4.806


  99 in total

1.  Sub-lingual immunotherapy: World Allergy Organization Position Paper 2009.

Authors:  G Walter Canonica; Jean Bousquet; Thomas Casale; Richard F Lockey; Carlos E Baena-Cagnani; Ruby Pawankar; Paul C Potter; Philippe J Bousquet; Linda S Cox; Stephen R Durham; Harold S Nelson; Giovanni Passalacqua; Dermot P Ryan; Jan L Brozek; Enrico Compalati; Ronald Dahl; Luis Delgado; Roy Gerth van Wijk; Richard G Gower; Dennis K Ledford; Nelson Rosario Filho; Erkka J Valovirta; Osman M Yusuf; Torsten Zuberbier; Wahiduzzaman Akhanda; Raul Castro Almarales; Ignacio Ansotegui; Floriano Bonifazi; Jan Ceuppens; Tomás Chivato; Darina Dimova; Diana Dumitrascu; Luigi Fontana; Constance H Katelaris; Ranbir Kaulsay; Piotr Kuna; Dèsirée Larenas-Linnemann; Manolis Manoussakis; Kristof Nekam; Carlos Nunes; Robyn O'Hehir; José M Olaguibel; Nerin Bahceciler Onder; Jung Won Park; Alfred Priftanji; Robert Puy; Luis Sarmiento; Glenis Scadding; Peter Schmid-Grendelmeier; Ester Seberova; Revaz Sepiashvili; Dirceu Solé; Alkis Togias; Carlo Tomino; Elina Toskala; Hugo Van Beever; Stefan Vieths
Journal:  Allergy       Date:  2009-12       Impact factor: 13.146

2.  Long-term efficacy of preseasonal grass pollen immunotherapy in children.

Authors:  P A Eng; M Reinhold; H P E Gnehm
Journal:  Allergy       Date:  2002-04       Impact factor: 13.146

3.  Low dose sublingual therapy in patients with allergic rhinitis due to house dust mite.

Authors:  G K Scadding; J Brostoff
Journal:  Clin Allergy       Date:  1986-09

4.  Randomized controlled trial of primary prevention of atopy using house dust mite allergen oral immunotherapy in early childhood.

Authors:  Zaraquiza Zolkipli; Graham Roberts; Victoria Cornelius; Bernie Clayton; Sarah Pearson; Louise Michaelis; Ratko Djukanovic; Ramesh Kurukulaaratchy; S Hasan Arshad
Journal:  J Allergy Clin Immunol       Date:  2015-06-12       Impact factor: 10.793

5.  Epicutaneous sensitization with protein antigen induces localized allergic dermatitis and hyperresponsiveness to methacholine after single exposure to aerosolized antigen in mice.

Authors:  J M Spergel; E Mizoguchi; J P Brewer; T R Martin; A K Bhan; R S Geha
Journal:  J Clin Invest       Date:  1998-04-15       Impact factor: 14.808

6.  Sublingual immunotherapy in peach allergy: monitoring molecular sensitizations and reactivity to apple fruit and Platanus pollen.

Authors:  B E García; E González-Mancebo; D Barber; S Martín; A I Tabar; Alonso Ma D Díaz de Durana; S Garrido-Fernández; G Salcedo; P Rico; M Fernández-Rivas
Journal:  J Investig Allergol Clin Immunol       Date:  2010       Impact factor: 4.333

Review 7.  Atopic march: link to upper airways.

Authors:  Jonathan M Spergel
Journal:  Curr Opin Allergy Clin Immunol       Date:  2005-02

8.  Oral immunotherapy of children with rhinoconjunctivitis due to birch pollen allergy. A double blind study.

Authors:  C Möller; S Dreborg; A Lanner; B Björkstén
Journal:  Allergy       Date:  1986-05       Impact factor: 13.146

9.  Safety and tolerability of a short ragweed sublingual immunotherapy tablet.

Authors:  Hendrik Nolte; Niran Amar; David I Bernstein; Bobby Q Lanier; Peter Creticos; Gary Berman; Amarjot Kaur; Jacques Hébert; Jennifer Maloney
Journal:  Ann Allergy Asthma Immunol       Date:  2014-05-14       Impact factor: 6.347

10.  Sublingual immunotherapy (SLIT) for house dust mites does not prevent new allergen sensitization and bronchial hyper-responsiveness in allergic rhinitis children.

Authors:  Jae Hyun Lim; Jin Youp Kim; Doo Hee Han; Chul Hee Lee; Seung-No Hong; Jee Hye Wee; Sue K Park; Chae-Seo Rhee
Journal:  PLoS One       Date:  2017-08-14       Impact factor: 3.240

View more
  3 in total

1.  TLR3 controls constitutive IFN-β antiviral immunity in human fibroblasts and cortical neurons.

Authors:  Daxing Gao; Michael J Ciancanelli; Peng Zhang; Oliver Harschnitz; Vincent Bondet; Mary Hasek; Jie Chen; Xin Mu; Yuval Itan; Aurélie Cobat; Vanessa Sancho-Shimizu; Benedetta Bigio; Lazaro Lorenzo; Gabriele Ciceri; Jessica McAlpine; Esperanza Anguiano; Emmanuelle Jouanguy; Damien Chaussabel; Isabelle Meyts; Michael S Diamond; Laurent Abel; Sun Hur; Gregory A Smith; Luigi Notarangelo; Darragh Duffy; Lorenz Studer; Jean-Laurent Casanova; Shen-Ying Zhang
Journal:  J Clin Invest       Date:  2021-01-04       Impact factor: 19.456

Review 2.  Asthma: Differential Diagnosis and Comorbidities.

Authors:  Nicola Ullmann; Virginia Mirra; Antonio Di Marco; Martino Pavone; Federica Porcaro; Valentina Negro; Alessandro Onofri; Renato Cutrera
Journal:  Front Pediatr       Date:  2018-10-03       Impact factor: 3.418

Review 3.  Predicting the course of asthma from childhood until early adulthood.

Authors:  Hans Jacob L Koefoed; Judith M Vonk; Gerard H Koppelman
Journal:  Curr Opin Allergy Clin Immunol       Date:  2022-04-01
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.